Privia Health Group, Inc. (NASDAQ:PRVA) Forecasted to Post Q3 2024 Earnings of $0.07 Per Share

Privia Health Group, Inc. (NASDAQ:PRVA) – Equities research analysts at William Blair raised their Q3 2024 earnings estimates for shares of Privia Health Group in a note issued to investors on Thursday, August 8th. William Blair analyst R. Daniels now expects that the company will post earnings of $0.07 per share for the quarter, up from their previous forecast of $0.06. The consensus estimate for Privia Health Group’s current full-year earnings is $0.19 per share.

Privia Health Group (NASDAQ:PRVA) last released its earnings results on Thursday, August 8th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). The business had revenue of $422.30 million for the quarter, compared to analyst estimates of $411.50 million. Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. Privia Health Group’s revenue was up 2.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.06 EPS.

Other research analysts have also issued research reports about the stock. Robert W. Baird initiated coverage on shares of Privia Health Group in a research note on Thursday, May 30th. They set an “outperform” rating and a $23.00 price objective on the stock. Truist Financial decreased their price target on shares of Privia Health Group from $28.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday, May 15th. Baird R W raised Privia Health Group to a “strong-buy” rating in a research note on Thursday, May 30th. Citigroup started coverage on Privia Health Group in a report on Monday, April 22nd. They set a “buy” rating and a $25.00 target price on the stock. Finally, Barclays lowered their price target on Privia Health Group from $22.00 to $19.00 and set an “equal weight” rating for the company in a report on Monday, May 20th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Privia Health Group currently has an average rating of “Moderate Buy” and a consensus target price of $24.54.

Privia Health Group Trading Up 3.9 %

Shares of PRVA opened at $20.05 on Monday. The stock has a market cap of $2.39 billion, a P/E ratio of 133.67, a price-to-earnings-growth ratio of 3.18 and a beta of 0.78. Privia Health Group has a 1 year low of $15.92 and a 1 year high of $27.34. The stock’s 50-day moving average price is $18.25 and its two-hundred day moving average price is $18.92.

Institutional Investors Weigh In On Privia Health Group

A number of large investors have recently added to or reduced their stakes in the business. Blair William & Co. IL boosted its position in Privia Health Group by 125.4% during the first quarter. Blair William & Co. IL now owns 51,564 shares of the company’s stock worth $1,010,000 after purchasing an additional 28,689 shares during the period. Oppenheimer Asset Management Inc. grew its stake in Privia Health Group by 27.1% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 234,991 shares of the company’s stock valued at $4,603,000 after buying an additional 50,042 shares during the last quarter. Handelsbanken Fonder AB grew its stake in Privia Health Group by 41.5% in the 4th quarter. Handelsbanken Fonder AB now owns 15,000 shares of the company’s stock valued at $345,000 after buying an additional 4,400 shares during the last quarter. Vanguard Group Inc. raised its holdings in Privia Health Group by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,278,334 shares of the company’s stock valued at $259,740,000 after acquiring an additional 274,345 shares during the period. Finally, Benjamin Edwards Inc. lifted its position in Privia Health Group by 44.9% during the fourth quarter. Benjamin Edwards Inc. now owns 3,239 shares of the company’s stock worth $75,000 after acquiring an additional 1,003 shares during the last quarter. Institutional investors own 94.48% of the company’s stock.

Insider Buying and Selling

In related news, Director Adam Boehler acquired 5,306 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were bought at an average price of $16.50 per share, for a total transaction of $87,549.00. Following the purchase, the director now directly owns 5,773,158 shares in the company, valued at approximately $95,257,107. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Adam Boehler bought 5,306 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were bought at an average cost of $16.50 per share, with a total value of $87,549.00. Following the acquisition, the director now owns 5,773,158 shares in the company, valued at $95,257,107. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas A. Mccarthy purchased 10,000 shares of Privia Health Group stock in a transaction that occurred on Thursday, May 23rd. The shares were acquired at an average price of $16.37 per share, with a total value of $163,700.00. Following the acquisition, the director now directly owns 52,611 shares of the company’s stock, valued at approximately $861,242.07. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 293,235 shares of company stock worth $4,745,481. Corporate insiders own 14.20% of the company’s stock.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.